$MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Jason V. Coloma
CEO
125
Employees
$26.92
Current Price
$2.17B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $205,031.44 | 7,500 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $205,031.44 | 7,500 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $205,031.44 | 7,500 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 11 | $2,611,793.02 | 91,968 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 22 | $4,655,297.35 | 170,466 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | Dandekar Atul CSBO | Sale | 400 | $27.89 | $11,156.00 | View Details |
| Jul 29, 2026 | Dandekar Atul CSBO | Sale | 7,100 | $27.31 | $193,875.44 | View Details |
| Jul 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 1,200 | $30.34 | $36,404.28 | View Details |
| Jul 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 13,409 | $29.86 | $400,459.78 | View Details |
| Jul 1, 2026 | Coloma Jason V Director | Sale | 2,593 | $29.98 | $77,726.21 | View Details |
| Jul 1, 2026 | Coloma Jason V Director | Sale | 30,311 | $29.95 | $907,920.54 | View Details |
| Jul 1, 2026 | Coloma Jason V Director | Sale | 1,597 | $30.44 | $48,606.13 | View Details |
| Jun 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $28.02 | $210,150.00 | View Details |
| Jun 23, 2026 | Coloma Jason V Director | Sale | 23,865 | $26.05 | $621,673.70 | View Details |
| Jun 22, 2026 | Coloma Jason V Director | Sale | 2,040 | $26.00 | $53,040.00 | View Details |
| Jun 22, 2026 | Coloma Jason V Director | Sale | 1,953 | $26.00 | $50,780.93 | View Details |
| Jun 1, 2026 | Coloma Jason V Director | Sale | 553 | $26.24 | $14,511.38 | View Details |
| Jun 1, 2026 | Coloma Jason V Director | Sale | 6,090 | $26.20 | $159,536.68 | View Details |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 1,600 | $26.36 | $42,172.16 | View Details |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 13,253 | $25.57 | $338,940.17 | View Details |
| May 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $26.34 | $197,553.75 | View Details |
| May 22, 2026 | Coloma Jason V Director | Sale | 4,504 | $26.00 | $117,104.45 | View Details |
| May 26, 2026 | Coloma Jason V Director | Sale | 25,582 | $26.02 | $665,515.73 | View Details |
| May 22, 2026 | Coloma Jason V Director | Sale | 2,478 | $26.00 | $64,428.00 | View Details |
| May 15, 2026 | Coloma Jason V Director | Sale | 116 | $26.00 | $3,016.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.